Evidence map›Paper›PMID 37970347›Full record

ArticleAmerican journal of cancer research2023

Preclinical trial of targeting the Hic-5-mediated pathway to prevent the progression of hepatocellular carcinoma.

Wen-Sheng Wu, Chuan-Chu Cheng, Yi-Hsuan Lee, Jia-Ling Wei, Rui-Fang Chen, Chen-Fang Lin, Ren-In You, Yen-Chang Chen, Hsiu-Ming Shih, Chi-Tan Hu and 3 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Wen-Sheng WuDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Chuan-Chu ChengDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Yi-Hsuan LeeDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Jia-Ling WeiDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Rui-Fang ChenDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Chen-Fang LinDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Ren-In YouDepartment of Laboratory Medicine and Biotechnology, College of Medicine, Tzu Chi University Hualien 97004, Taiwan.
Yen-Chang ChenDepartment of Anatomical Pathology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Hsiu-Ming ShihInstitute of Biomedical Sciences, Academia Sinica Taipei 11529, Taiwan.
Chi-Tan HuDivision of Gastroenterology, Department of Medicine, Research Centre for Hepatology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Hsin-Hou ChangDepartment of Molecular Biology and Human Genetics, Tzu Chi University Hualien 97004, Taiwan.
Ming-Che LeeDivision of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University Taipei 110, Taiwan.
Yen-Cheng ChenDivision of General Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 97004, Taiwan.
Tzu Chi University · TWTzu Chi Foundation · TWInstitute of Biomedical Sciences, Academia Sinica · TWWan Fang Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The poor prognosis of hepatocellular carcinoma (HCC) was ascribed to metastasis. Targeted therapy aiming at the molecules along the metastatic pathway is a promising therapeutic strategy. Among them, hydrogen peroxide inducible clone-5 (Hic-5) is highlighted. Hic-5, discovered as a reactive oxygen species (ROS)-inducible gene, was identified to be an adaptor protein in focal adhesion and a critical signaling mediator upregulated in various cancers including HCC. Moreover, Hic-5 may regulate epithelial-mesenchymal transition (EMT) transcription factor Snail and its downstream mesenchymal genes including fibronectin and matrix metalloproteinase-9 required for migration and invasion of HCC. However, the comprehensive Hic-5-mediated pathway was not established and whether Hic-5 can be a target for preventing HCC progression has not been validated

Indexed as

Hic-5metastasisreactive oxygen species modulatorstable nucleic acids lipid nanoparticlesZNF395

Identifiers

PMID37970347
PMCPMC10636688
OpenAlexW4388737049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.